Gene therapy specialist AskBio Inc, a wholly owned and independently operated subsidiary of German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY), announced on Wednesday that the US Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for AB-1009.
The product is an investigational adeno-associated virus (AAV) gene therapy being developed for the treatment of late-onset Pompe disease.
With this announcement, the AB-1009 programme progresses to Phase 1/2 and AskBio will commence a clinical trial in the United States to explore the safety of AB-1009. The company anticipates recruiting the first patient in early 2026.
In September 2024, AskBio formed a strategic collaboration with Belief BioMed (BBM) to explore the potential for new gene therapies. BBM granted AskBio a sublicence to use the proprietary AAV capsid in the AB-1009 programme and provided AAV vector production services.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA